摘要
目的探讨布地奈德混悬液联合氨溴索雾化吸入治疗慢性阻塞性肺疾病(COPD)急性加重期患者的临床疗效。方法选择急性加重期的COPD患者80例,分为观察组和对照组各40例。对照组给予持续低流量吸氧、抗感染、平喘、止咳化痰及维持水电解质酸碱平衡等常规治疗。观察组在常规治疗的基础上,给予布地奈德混悬液联合氨溴索雾化吸入。观察比较2组各项临床疗效指标。结果观察组呼吸困难程度总有效率为97.5%高于对照组的80.0%,差异有统计学意义(P<0.05)。观察组肺部啰音总有效率为95.0%高于对照组的75.0%,差异有统计学意义(P<0.05)。观察组无明显不良反应发生。结论布地奈德联合氨溴索雾化吸入治疗COPD急性加重期疗效好,无明显不良反应,值得临床推广。
Objective To investigate the efficacy of nebulized budesonide combined with ambroxol atomization inhala-tion in the treatment of patients with acute exacerbation of chronic obstructive pulmonary disease（COPD）. Methods 80 ca-ses of patients with acute exacerbations of COPD were divided into the observation group and control group,each of 40 cases. The control group was given continuous low flow oxygen,anti infection,bronchodilators,cough suppressant and expectorant, maintaining water electrolyte and acid-base balance and other conventional treatment. The observation group was given nebuliz-ed budesonide and ambroxol atomization inhalation on the basis of the conventional therapy. The clinical variable of 2 groups were observed and compared. Results The total effective rate of expiratory dyspnea in the observation group was 97. 5% , which was higher than 80. 0% of the control group,the difference was statistically significant（P〈0. 05）. The total effective rate of pulmonary rales in the observation group was 95. 0% ,which was higher than 75. 0% of the control group,the difference was statistically significant（P〈0. 05）. The observation group had no obvious adverse reaction. Conclusion The nebulized budesonide and ambroxol atomization inhalation have a positive curative effect in the treatment of acute exacerbation of COPD, with no obvious adverse reaction,which is worthy of clinical promotion.
出处
《临床合理用药杂志》
2015年第2期9-10,共2页
Chinese Journal of Clinical Rational Drug Use
关键词
慢性阻塞性肺疾病
急性加重期
布地奈德
氨溴索
雾化吸入
Chronic obstructive pulmonary disease
Acute exacerbation
Budesonide
Ambroxol
Aerosol inhalation
